Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation (SEGOVA)

Forever Young d.o.o.

Status and phase: Unknown; Phase 2; Phase 1

Conditions: Premature Ovarian Failure 10; Premature Ovarian Failure 11; Premature Ovarian Failure 8; Premature Ovarian Failure 1; Ovarian Insufficiency; Premature Ovarian Failure 6; Premature Ovarian Failure 7; Premature Ovarian Failure 12; Premature Ovarian Failure; Ovarian Failure, Premature; Premature Ovarian Failure 9; Premature Ovarian Failure 3; Ovarian Failure Secondary; Premature Ovarian Failure 14; Ovarian Insufficiency, Primary; Menopause, Premature; Premature Ovarian Failure 5; Menopause; Ovarian Failure; Premature Ovarian Failure 2A; Menopause Ovarian Failure; Premature Ovarian Failure 2B; Premature Ovarian Failure 13; Premature Ovarian Failure 4

Treatments: Combination Product: SEGOVA procedure

Study type: Interventional

Funder types: Other

Identifiers

NCT04009473

IRB No 63/295/2015

Details and patient eligibility

About

SEGOVA procedure includes - Stem cell therapy, G - Growth factor Platelet Plasma Rich therapy and in Vitro Activation of the ovaries.

Full description

The current study seeks to demonstrate how integrative ovarian rejuvenation program called SEGOVA influence the restoration of hormone stability and increase in the number of follicles in ovarian failure patients. The recruitment of patients and data collection would be performed at three sites: The Special Hospital Jevremova Belgrade, Saint James Hospital Malta, and Remedica Skopje Hospital, Macedonia. A 50-100 of Infertile women with ovarian failure will be included in the period between July 2019 - December 2021. The patients would be coded when entering the program, and all personal information would be protected. Information about medical treatment and background will be held on both paper and electronic case report forms.The result of the procedure will be maintained in the research database with blinding to clinical physician that will perform post procedure follow-up of those patients. In case of a complication, possibly related to treatment, the case will be unblinded.

The first day of procedure, autologous platelet rich plasma (PRP) is obtained from 100-120 mL of whole blood. After separation 4 mL of PRP is obtained. Concentration of platelets is optimised on 6-8x baseline and 2-3x leucocytes baseline. For activation of PRP autologous thrombin is used in ratio 1:10.

On the same day the laparoscopic cortical resection of the ovary is performed in standard technique. Ovarian cortex sample is minced in a petri dish.The volume of activated PRP (4 mL) is mixed with ovarian fragments and incubated for the next 48h at 37℃ and 5% CO2. After 48h, the bone marrow sampling from tibia under general anesthesia is performed to obtain bone marrow. After centrifugation the Bone Marrow Aspirate Concentrate (BMAC) with nucleated cells is obtained (3 +/- 1,5 mL).

Finally, after the 48h has passed from ovarian cortex tissue incubation, fragmented tissue of the ovary with 4 mL of PRP will be injected together with 3 +/- 1.5 mL BMAC into the subcortical region of the both ovaries as transvaginal ultra sound guided injection.

After the procedure, during one year follow up, hormone levels of follicle stimulating hormone (FSH), luteinizing hormone (LH),estradiol (E2), progesterone (PG) and anti-mullerian hormone (AMH) would be measured and the follicle numbers would be monitored to provide insight regarding the ovarian function.To investigate the changes in hormone levels, comparisons of the levels detected prior to the intervention, and 3, 6 and 12 months post-intervention, would be performed using Wilcoxon's rank test. Descriptive statistics will be provided for each variable as mean or median number, frequency, percentage, table or graph.

In patients with oocytes retrieved after SEGOVA procedure, standard In Vitro Fertilization protocol would be performed,and fertilization, cleavage and clinical pregnancy rates will be monitored.

Enrollment: 100 estimated patients

Sex: Female

Ages: 25+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Confirmed informed consent, signature and date

• A woman over 25 years of age
• Primary or secondary amenorrhea for at least 3 months
• Hormone Anti Mullerian Hormone values <_0.42 ng / ML and Follicle stimulating hormone FSH> 20 IU / L, and / or failure of previous attempts of assisted reproductive techniques due to limited ovarian response (less than 3 oocyte cells obtained).
• The proper karyotype 46, XX.
• Presence of at least one ovary

Exclusion criteria

• Currently pregnancy or breastfeeding
• Presence of Sexually Transmitted Disease (STD positive)
• There is presence of acute infection (C Reactive Protein>5)
• There is an anamnesis or evidence of existing gynecological malignancy
• The presence of adnexal masses indicating the need for further evaluation.
• It has a contraindication to laparoscopic surgery and / or general anesthesia
• Over the past two weeks, use of the following medicines: Oral or systemic corticosteroids, hormones (estrogen, progestins, oral contraceptives), Danazol, anticoagulants, herbal or botanical supplements with potential hormonal effects.
• Type I diabetes mellitus
• Known significant anemia (hemoglobin <8 g / dL), Severe venous thrombosis and / or pulmonary embolism, Cerebrovascular disease, Presence of heart disease, Premature kidney disease (defined as urea in the blood> 30 mg / dL or serum creatinine> 1.6 mg / dL).

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

SEGOVA Intervention Group

Experimental group

Description:

Intervention group of 50-100 patients with ovarian failure would be subjected to a three-day procedure named SEGOVA: bone marrow derived StEm cell treatment, Growth factor incubation and Ovarian In Vitro Activation. After the procedure, one year follow up of hormones measurements (follicle stimulating hormone (FSH), luteinizing hormone (LH),estradiol (E2), progesterone (PG) and anti-mullerian hormone (AMH)) and follicle counts would be established. In patients with oocytes retrieved after SEGOVA procedure, standard In Vitro Fertilization protocol would be performed. The fertilization, cleavage and clinical pregnancy rate will be monitored.

Treatment:

Combination Product: SEGOVA procedure